Welcome to our dedicated page for Elutia SEC filings (Ticker: ELUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elutia Inc. (ELUT) SEC filings page on Stock Titan centralizes the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret complex documents. Elutia is a regenerative medicine company that develops drug-eluting biomatrix products, and its filings provide detailed insight into how this business is structured, financed and governed.
Key documents for ELUT include Form 10-K annual reports and Form 10-Q quarterly reports, which discuss Elutia’s drug-eluting biomatrix platform, segment information such as historical Device Protection, Women’s Health and Cardiovascular activities, risk factors, and management’s analysis of operating performance. These reports also describe the company’s focus on NXT-41 and NXT-41x in plastic and reconstructive surgery and summarize prior divestitures, including the Orthobiologics business and the CIED/BioEnvelope business.
Elutia files frequent Form 8-K current reports to document material events. Recent 8-Ks have covered the agreement and closing of the sale of its CIED business to Boston Scientific and Cardiac Pacemakers Inc., amendments to its credit facility with SWK Funding LLC, the use of sale proceeds to repay that facility, board changes, and a Nasdaq notice regarding minimum bid price compliance. These filings also attach press releases with financial results and transaction details, giving additional context on cash flows, debt reduction and strategic focus.
Investors can also use this page to access proxy and governance filings when available, as well as any Form 4 insider transaction reports that disclose trades by directors and officers. Stock Titan’s AI features summarize lengthy filings, highlight sections on regulatory risk, litigation related to products such as FiberCel, royalty and revenue interest obligations, and explain how transactions like the BioEnvelope sale affect Elutia’s balance sheet and future plans.
By reviewing ELUT’s SEC filings alongside AI-generated explanations, users can quickly understand the regulatory history, capital structure changes and strategic decisions that shape Elutia’s drug-eluting biomatrix business.
Elutia (ELUT) reported Board changes. The Board elected Guido Neels effective October 9, 2025, and appointed him to the Audit Committee. In line with the non-employee director policy, he received an option to purchase 171,916 shares at an exercise price of $0.88 per share, vesting in three equal annual installments and becoming fully exercisable on October 9, 2028.
The company noted an existing consulting agreement with Mr. Neels from December 1, 2023, under which he was granted 50,000 RSUs on December 20, 2023 and 25,000 RSUs on March 5, 2025, each vesting in quarterly installments through December 2025. Separately, Maybelle Jordan and W. Matthew Zuga resigned from the Board effective October 8, 2025, and the company stated their resignations were not due to any disagreement.
Elutia Inc. (ELUT) reported a director stock option grant covering 171,916 shares at an exercise price of $0.88 on October 9, 2025. The option vests in three equal annual installments and becomes fully exercisable on October 9, 2028, with an expiration date of October 9, 2035. After the grant, 171,916 derivative securities were beneficially owned, held directly.
Elutia Inc. (ELUT) filed a Form 3 reporting a director’s holdings. The filing lists 62,500 shares of Class A Common Stock beneficially owned, held directly. It also discloses restricted stock units granted on December 20, 2023 for 50,000 RSUs vesting in eight equal installments through December 1, 2025, and on March 5, 2025 for 25,000 RSUs vesting in four equal installments through December 10, 2025. The event date is October 9, 2025.
Elutia Inc. announced the closing of a sale of substantially all assets related to its cardiac implantable electronic device (CIED) business to Boston Scientific Corporation and Cardiac Pacemakers, Inc., under an Asset Purchase Agreement dated September 8, 2025. As part of the transaction, Elutia Med LLC amended its royalty agreement with Ligand Pharmaceuticals: Ligand agreed to consent to the sale and released its security interest in the CIED assets, and Elutia Med paid $1.1M in accrued unpaid royalties. The Royalty Agreement requires a 5.0% royalty on future sales of specified products through May 31, 2027, with annual minimum payments of $4.4M. Exhibits filed include the Asset Purchase Agreement, the Consent/Amendment with Ligand, a press release, and unaudited pro forma financial information.
Elutia Inc. (ELUT) Chief Scientific Officer Michelle LeRoux Williams reported the vesting of restricted stock units on 09/10/2025 that resulted in the acquisition of 12,500 shares of Class A common stock. The filing shows 3,950 shares were withheld to satisfy tax withholding, leaving the reporting person with 97,335 shares beneficially owned after the transaction. The underlying RSU grant of 150,000 was originally made on January 31, 2024, with a defined multi-quarter vesting schedule through December 10, 2026.
Matthew Ferguson, Chief Financial Officer of Elutia Inc. (ELUT), reported insider transactions dated 09/10/2025. On that date he received 29,000 shares of Class A Common Stock upon vesting of restricted stock units, which increased his beneficial ownership to 379,417 shares. The filing also shows 10,348 shares were withheld to satisfy tax withholding at a reported price of $1.36, reducing the reported holding to 369,069 shares. The filing discloses the original RSU grants made on January 31, 2024 (150,000 and 50,000 RSUs) and the vesting schedules for those grants. The form is signed by Mr. Ferguson on 09/11/2025.
C. Randal Mills, who serves as President, Chief Executive Officer and a director of Elutia Inc. (ELUT), reported the vesting of 27,083 restricted stock units (RSUs) on 09/10/2025. Those vested RSUs converted into Class A common stock and are reported as an acquisition. The issuer withheld 9,664 shares to satisfy tax withholding at an indicated withholding price of $1.36 per share.
Following these transactions the filing shows the reporting person beneficially owning 338,586 shares of Class A common stock. The filing also discloses that on January 31, 2024 the reporting person was granted 487,500 RSUs, of which 297,916 RSUs are shown as derivative securities still outstanding and subject to the vesting schedule described in the filing.
Elutia Inc. agreed to sell substantially all assets of its cardiac implantable electronic device (CIED) business, including CanGaroo, EluPro and related envelope products, to Boston Scientific Corporation and Cardiac Pacemakers Inc. for up to $88 million in cash. The price includes $80 million payable at closing and $8 million held in escrow for twelve months as an indemnity holdback.
The CIED assets comprise substantially all assets in Elutia’s Device Protection segment. Closing is subject to customary conditions, including required consents, no prohibitive laws or orders, no material adverse effect on the CIED business, and transfer of employees, and is expected in the fourth quarter of 2025.
Elutia agreed to five-year non‑competition restrictions in business lines related to the current CIED business and entered into customary mutual indemnification arrangements allocating liabilities between the parties for pre‑ and post‑closing periods and specified excluded assets and liabilities.
Elutia Inc. disclosed that it entered into a Fifth Amendment to the Credit Agreement dated August 14, 2025 among Elutia Inc., SWK Funding LLC (as Agent) and the lenders party thereto. The 8-K lists this amendment as an exhibit (Exhibit 10.1) and cites Items 1.01 (entry into a material definitive agreement) and 2.03 (creation of a direct financial obligation or off-balance-sheet arrangement). The filing includes an Inline XBRL cover page (Exhibit 104). The document provides the existence and date of the amendment but does not disclose the amendment's terms, financial amounts, covenants, maturity changes, or other transactional details.
Elutia, Inc. reported continued operating losses and significant legal and liquidity risks in its Form 10-Q. For the six months ended June 30, 2025, the company recorded a net loss of $13.5 million and an accumulated deficit of $243.1 million. Cash used in operations totaled $17.1 million year-to-date and the company expects ongoing cash outflows for the rest of 2025, raising concerns about its ability to achieve and sustain profitability.
The company completed the sale of its Orthobiologics Business (initial gain recognized of $6.0 million in 2023 and an additional $0.2 million in 2024) with potential earn-outs of up to $20 million and a $1.5 million indemnity holdback. Material litigation includes extensive FiberCel and VBM claims: the company recorded $13.3 million as a probable liability for 47 FiberCel cases and $3.7 million for VBM-related matters, with substantial settlements already paid and insurance receivables recorded. Elutia has a secured SWK loan facility with a weighted average interest rate of 12.6% for the three months ended June 30, 2025 and amended covenants requiring a minimum liquidity of $8.0 million. The company discloses substantial risks around commercialization of EluPro, supplier dependence, indemnities and contingent liabilities.